Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy

Research output: Contribution to journalArticlepeer-review

61 Scopus citations

Abstract

Purpose To retrospectively evaluate in patients with non-arteritic ischaemic optic neuropathy (NAION) whether aspirin reduces the frequency of second eye involvement.Methods In 52 patients who presented with NAION between 1984 and 1997 adequate information was available regarding use of aspirin, presence of risk factors and second eye involvement.Results Second eye involvement was noted in 8 of 16 patients (50%) who did not receive aspirin, in 3 of 8 patients (38%) who received 100 mg/day aspirin and in only 5 of 28 patients (18%) who received aspirin 325 mg/day. Moreover, mean time to second eye involvement was 63 months in patients who did not receive aspirin versus 156 months in patients who received aspirin 325 mg/day.Conclusion Our results strongly suggest that aspirin at 325 mg/day may be effective in reducing the frequency of second eye involvement with NAION.

Original languageEnglish
Pages (from-to)357-359
Number of pages3
JournalEye (Basingstoke)
Volume13
Issue number3
DOIs
StatePublished - May 1999

Keywords

  • Anterior ischaemic optic neuropathy
  • Aspirin

Fingerprint

Dive into the research topics of 'Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy'. Together they form a unique fingerprint.

Cite this